FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912697493> ?p ?o ?g. }

• W2912697493 abstract "Lymphoid organ neogenesis takes place in chronically inflamed tissues including cancer and yields the development of tertiary lymphoid structures (TLS). TLS are ectopic lymphoid organs that activate antigen specific T-cells and B cells in infection and autoimmunity and correlate with prolonged survival in various cancer types. This suggests that TLS contribute to protective anti-tumor immunity. Therefore, promoting the development of tumor-associated TLS could be a novel immunotherapeutic approach. However, the molecular and cellular mechanisms of TLS development in human cancer or how TLS contribute to survival are largely not understood. Here we used multiparameter immunofluorescence and digital pathology to quantify TLS and to characterize their cellular composition and tissue context in cohorts of lung squamous cell carcinoma (LSCC, n=138), colorectal cancer (CRC, n=111), clear cell renal cell carcinoma (ccRCC, n=50) and bladder cancer (BC, n=33) patients. Furthermore, we established an experimental model to characterize TLS development and its impact on tumor-specific immunity. We discovered that TLS development and maturation followed the same steps in all analyzed tumor types as well as in the lungs of mice in our experimental model. First, B and T lymphocytes accumulated around blood vessels. Second, a network of follicular dendritic cells developed within the lymphocytic aggregate, and third, a germinal center (GC) reaction was activated. Additionally, we identified a niche of CXCL13+ perivascular stroma and CXCL12+LTB+ and PD-L1+ epithelial cells that were associated with TLS in LSCC. We found that the number of tumor-associated TLS was an independent prognostic factor for prolonged survival in untreated LSCC, CRC and BC, but not in ccRCC patients or in LSCC and BC patients who were treated with neoadjuvant chemotherapy. By comparing the chemotherapy-treated and untreated cohorts we observed that the number of TLS was not changed but TLS maturation (i.e. GC formation) was significantly impaired after chemotherapy. This difference was at least partially dictated by corticosteroids, which are commonly used to treat the side effects of chemotherapy of LSCC patients. We further studied the mechanisms underlying TLS development using the experimental model. We identified a combination of stimuli that induces the development of mature TLS in the lungs of mice. Besides inflammatory stimuli, a foreign antigen was necessary to achieve a significant increase in TLS numbers and maturation stage, suggesting that cognate interactions are crucial for lymphoid organ neogenesis. This is further supported by our observation that CRC patients with microsatellite instability, which presumably results in more neoantigens, had an increased proportion of mature TLS. The negative impact of corticosteroids on TLS development was confirmed in this model. In summary, we propose that GC+ TLS represent the relevant TLS phenotype contributing to survival in different tumor types. Lymphoid organ neogenesis is negatively affected by corticosteroids, which might impair the spontaneous as well as therapy-induced anti-tumor immunity. The established experimental model will allow investigation of the mechanisms of TLS development and function in cancer and assessment of their therapeutic potential. Citation Format: Karina Silina, Alex Soltermann, Chiara Burkhardt, Farkhondeh Movahedian Attar, Ruben Casanova, Alessandra Curioni-Fontecedro, Holger Moch, Florian Posch, Thomas Winder, Nick van Dijk, Charlotte Voskuilen, Michiel van der Heijden, Maries van den Broek. Harnessing lymphoid organ neogenesis as a novel prognostic biomarker and therapeutic target [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A113." @default.
• W2912697493 created "2019-02-21" @default.
• W2912697493 creator A5003753570 @default.
• W2912697493 creator A5004143670 @default.
• W2912697493 creator A5005593510 @default.
• W2912697493 creator A5009120799 @default.
• W2912697493 creator A5015439827 @default.
• W2912697493 creator A5026218275 @default.
• W2912697493 creator A5028420728 @default.
• W2912697493 creator A5035950152 @default.
• W2912697493 creator A5039484803 @default.
• W2912697493 creator A5041905925 @default.
• W2912697493 creator A5046360521 @default.
• W2912697493 creator A5062805085 @default.
• W2912697493 creator A5063566935 @default.
• W2912697493 date "2019-02-01" @default.
• W2912697493 modified "2023-09-26" @default.
• W2912697493 title "Abstract A113: Harnessing lymphoid organ neogenesis as a novel prognostic biomarker and therapeutic target" @default.
• W2912697493 doi "https://doi.org/10.1158/2326-6074.cricimteatiaacr18-a113" @default.
• W2912697493 hasPublicationYear "2019" @default.
• W2912697493 type Work @default.
• W2912697493 sameAs 2912697493 @default.
• W2912697493 citedByCount "0" @default.
• W2912697493 crossrefType "proceedings-article" @default.
• W2912697493 hasAuthorship W2912697493A5003753570 @default.
• W2912697493 hasAuthorship W2912697493A5004143670 @default.
• W2912697493 hasAuthorship W2912697493A5005593510 @default.
• W2912697493 hasAuthorship W2912697493A5009120799 @default.
• W2912697493 hasAuthorship W2912697493A5015439827 @default.
• W2912697493 hasAuthorship W2912697493A5026218275 @default.
• W2912697493 hasAuthorship W2912697493A5028420728 @default.
• W2912697493 hasAuthorship W2912697493A5035950152 @default.
• W2912697493 hasAuthorship W2912697493A5039484803 @default.
• W2912697493 hasAuthorship W2912697493A5041905925 @default.
• W2912697493 hasAuthorship W2912697493A5046360521 @default.
• W2912697493 hasAuthorship W2912697493A5062805085 @default.
• W2912697493 hasAuthorship W2912697493A5063566935 @default.
• W2912697493 hasConcept C121608353 @default.
• W2912697493 hasConcept C126322002 @default.
• W2912697493 hasConcept C142724271 @default.
• W2912697493 hasConcept C159654299 @default.
• W2912697493 hasConcept C165220095 @default.
• W2912697493 hasConcept C203014093 @default.
• W2912697493 hasConcept C2778453870 @default.
• W2912697493 hasConcept C2779306644 @default.
• W2912697493 hasConcept C2780093864 @default.
• W2912697493 hasConcept C502942594 @default.
• W2912697493 hasConcept C71924100 @default.
• W2912697493 hasConcept C86803240 @default.
• W2912697493 hasConcept C96926380 @default.
• W2912697493 hasConceptScore W2912697493C121608353 @default.
• W2912697493 hasConceptScore W2912697493C126322002 @default.
• W2912697493 hasConceptScore W2912697493C142724271 @default.
• W2912697493 hasConceptScore W2912697493C159654299 @default.
• W2912697493 hasConceptScore W2912697493C165220095 @default.
• W2912697493 hasConceptScore W2912697493C203014093 @default.
• W2912697493 hasConceptScore W2912697493C2778453870 @default.
• W2912697493 hasConceptScore W2912697493C2779306644 @default.
• W2912697493 hasConceptScore W2912697493C2780093864 @default.
• W2912697493 hasConceptScore W2912697493C502942594 @default.
• W2912697493 hasConceptScore W2912697493C71924100 @default.
• W2912697493 hasConceptScore W2912697493C86803240 @default.
• W2912697493 hasConceptScore W2912697493C96926380 @default.
• W2912697493 hasLocation W29126974931 @default.
• W2912697493 hasOpenAccess W2912697493 @default.
• W2912697493 hasPrimaryLocation W29126974931 @default.
• W2912697493 hasRelatedWork W2007378449 @default.
• W2912697493 hasRelatedWork W2044445004 @default.
• W2912697493 hasRelatedWork W2067900714 @default.
• W2912697493 hasRelatedWork W2080554552 @default.
• W2912697493 hasRelatedWork W2318948517 @default.
• W2912697493 hasRelatedWork W2406415524 @default.
• W2912697493 hasRelatedWork W2535232402 @default.
• W2912697493 hasRelatedWork W2547059043 @default.
• W2912697493 hasRelatedWork W2740886521 @default.
• W2912697493 hasRelatedWork W2790255072 @default.
• W2912697493 hasRelatedWork W2886190874 @default.
• W2912697493 hasRelatedWork W2899585608 @default.
• W2912697493 hasRelatedWork W2944144170 @default.
• W2912697493 hasRelatedWork W3046555517 @default.
• W2912697493 hasRelatedWork W3128150627 @default.
• W2912697493 hasRelatedWork W3130984664 @default.
• W2912697493 hasRelatedWork W3132085051 @default.
• W2912697493 hasRelatedWork W3167727425 @default.
• W2912697493 hasRelatedWork W3179443060 @default.
• W2912697493 hasRelatedWork W3210125031 @default.
• W2912697493 isParatext "false" @default.
• W2912697493 isRetracted "false" @default.
• W2912697493 magId "2912697493" @default.
• W2912697493 workType "article" @default.